Granisetrón Aurovitas Spain (Granisetron)

Granisetrón Aurovitas Spain is indicated for the prevention of nausea and vomiting in specific clinical situations.

• Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients.
• Prevention of postoperative nausea and vomiting (PONV) after surgical procedures.
• Use as part of a multimodal antiemetic regimen when high emetogenic risk is anticipated.
• Administration before the start of chemotherapy or anesthesia to maximize efficacy.
• May be considered in patients who have experienced inadequate control with other antiemetics.
• Can be combined with dexamethasone or a neurokinin‑1 antagonist to enhance antiemetic protection.

The safety profile of granisetron includes both common and less frequent serious adverse events that have been reported in clinical use.

Common

• Headache, a mild to moderate pain often described as throbbing.
• Constipation, reduced bowel movements or difficulty passing stool.
• Diarrhea, loose or watery stools occurring intermittently.
• Fatigue, a feeling of tiredness or lack of energy.
• Dizziness, a sensation of lightheadedness or unsteadiness.
• Dry mouth, reduced salivation that may cause throat discomfort.

Serious

• Severe allergic reaction (anaphylaxis), including rash, swelling, and breathing difficulty.
• Cardiac arrhythmia, irregular heartbeats that may require medical attention.
• Prolonged QT interval, an electrocardiographic change that can increase risk of arrhythmias.

When prescribing or using Granisetrón Aurovitas Spain, clinicians should consider several precautionary measures to ensure safe administration.

• Assess patient history for cardiac disease, especially known QT prolongation.
• Use caution in patients with electrolyte abnormalities such as low potassium or magnesium.
• Evaluate for hypersensitivity to granisetron or other 5‑HT3 antagonists before initiating therapy.
• Adjust dosing in patients with severe hepatic impairment as metabolism may be reduced.
• Monitor for signs of constipation or bowel obstruction, particularly in postoperative patients.
• Consider alternative antiemetics in pregnant or breastfeeding women due to limited safety data.

Granisetron may interact with other medications, affecting its efficacy or safety profile.

Avoid

• Concomitant use with drugs that significantly prolong the QT interval, such as certain antiarrhythmics or antipsychotics.
• Co‑administration with potent CYP3A4 inhibitors, which can increase granisetron plasma concentrations.
• Avoid simultaneous use with other 5‑HT3 antagonists, as this provides no additional benefit and may increase adverse effects.

Use with caution

• Combining with other serotonergic agents may increase the risk of serotonin syndrome; monitor patients closely.
• Use with other antiemetics that have overlapping mechanisms, as additive effects on cardiac conduction may occur.
• Caution when administered with drugs that affect electrolyte balance, such as diuretics, which could predispose to cardiac arrhythmias.